Dr. Evelyn Shabad and Carol Gilad share insights on follow-up, short-term treatment, and surprising results without major side effects.

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

Lifestyle Expert Jennifer Bonner discusses chronic lymphocytic leukemia, or CLL, and the exciting advancements in its ...

Video content above is prompted by the following: Let’s conclude by discussing our perspectives on the future of CLL treatment. How do you envision the CLL patient experience evolving in the coming ...

Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic ...

Alessandra Ferrajoli, MD, discusses the comorbidities that can impact the management of patients with chronic lymphocytic leukemia and some of the available treatment options in this space.

Treatment with Brukinsa may lower the rates of switching therapies compared with Calquence and Imbruvica in chronic ...

Richter transformation involves the evolution of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) into an ...

Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic ...

Investigators concluded that while BTK C481 mutations are common with both acalabrutinib and ibrutinib, the types and frequencies of mutations vary, indicating different resistance mechanisms for each ...

Richter transformation describes the development of an aggressive lymphoma in patients with chronic lymphocytic leukaemia, ...

HOUSTON — Bruton's tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the ...